Ironwood Pharmaceuticals Announces Initiation Of Phase 2 Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation (OIC). Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc, Ironwood’s co-development and co-promotion partner for linaclotide in the United States.

Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is not currently approved for the treatment of OIC.

Help employers find you! Check out all the jobs and post your resume.

Back to news